OncoTherapy Science

4564.TTSE GROWTHPharmaceutical

Key numbers · FY ended 2026-03

Revenue¥809m+7.8% YoY Operating income−¥810m—Net income (owners)−¥911m—Total assets¥2.4bn+104.2% YoY EPS (basic)¥-2.77+11.2% YoY

Full financial history and reports →

Stock price4564 · View chart ↗

Open the price chart on TradingView.

Latest filings

Tue, May 19 · JST1 filing

16:07MATERIALOncoTherapy Science · Change of independent auditor

Tue, Mar 24 · JST1 filing

16:035% STAKEOncoTherapy Science · Long Corridor Asset Management Limited · 10.61% → 9.36%−1.25pp

Wed, Dec 10 · JST1 filing

15:465% STAKEOncoTherapy Science · Long Corridor Asset Management Limited · 18.81%new 18.81%

Mon, Sep 1 · JST1 filing

15:305% STAKEOncoTherapy Science · Long Corridor Asset Management Limited · 10.04% → 9.15%−0.89pp

Tue, Jul 1 · JST1 filing

16:335% STAKEOncoTherapy Science · Long Corridor Asset Management Limited · 15.19% → 11.51%−3.68pp

All filings →

Major holders (5%+) · 1

Holder	Stake	Change	Filed
Yusuke Nakamura	6.05%	-0.44pp	2026-09-11

Each holder's own ratio from its most recent large-shareholding report.